CN103333168B - 一种酰胺类化合物及其制备方法与应用 - Google Patents
一种酰胺类化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN103333168B CN103333168B CN201310311172.6A CN201310311172A CN103333168B CN 103333168 B CN103333168 B CN 103333168B CN 201310311172 A CN201310311172 A CN 201310311172A CN 103333168 B CN103333168 B CN 103333168B
- Authority
- CN
- China
- Prior art keywords
- formula
- amides
- naphthyridines
- preparation
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 150000001408 amides Chemical class 0.000 title claims abstract description 25
- -1 methylol, aminomethyl Chemical group 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 18
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 12
- 241000700605 Viruses Species 0.000 abstract description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 6
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 150000002367 halogens Chemical class 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 3
- 150000002460 imidazoles Chemical class 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 20
- 238000012512 characterization method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000007821 HATU Substances 0.000 description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 241000711549 Hepacivirus C Species 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XDDZLUYCWFGXET-UHFFFAOYSA-N 2,5-bis(trifluoromethyl)-1h-imidazole Chemical compound FC(F)(F)C1=CNC(C(F)(F)F)=N1 XDDZLUYCWFGXET-UHFFFAOYSA-N 0.000 description 5
- JYUHRYOZLKMRQK-UHFFFAOYSA-N bromomethane propan-2-one Chemical compound CBr.CC(=O)C JYUHRYOZLKMRQK-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- UTUSYSDVLOWRJA-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)-1h-imidazole Chemical compound CC1=NC=C(C(F)(F)F)N1 UTUSYSDVLOWRJA-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- CRADWWWVIYEAFR-UHFFFAOYSA-N 1,8-naphthyridin-2-amine Chemical class C1=CC=NC2=NC(N)=CC=C21 CRADWWWVIYEAFR-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- GJIYFZYSQJGEHK-UHFFFAOYSA-N NCCNC(c(nc1cc2)c[n]1c1c2c(C(F)(F)F)cc(C(F)(F)F)n1)=O Chemical compound NCCNC(c(nc1cc2)c[n]1c1c2c(C(F)(F)F)cc(C(F)(F)F)n1)=O GJIYFZYSQJGEHK-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
化合物 | IC50±SEM(μM) | 化合物 | IC50±SEM(μM) |
I1 | 0.046±0.024 | I6 | 0.0199±0.0127 |
I2 | 0.158±0.101 | II1 | 0.013±0.0085 |
I3 | 0.066±0.043 | II2 | 0.048±0.0316 |
I4 | 1.83±0.700 | II3 | 0.0166±0.0016 |
I5 | 0.0688±0.0461 | IFNa-2b | 1.117±0.854IU |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310311172.6A CN103333168B (zh) | 2013-07-23 | 2013-07-23 | 一种酰胺类化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310311172.6A CN103333168B (zh) | 2013-07-23 | 2013-07-23 | 一种酰胺类化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103333168A CN103333168A (zh) | 2013-10-02 |
CN103333168B true CN103333168B (zh) | 2015-08-05 |
Family
ID=49241387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310311172.6A Expired - Fee Related CN103333168B (zh) | 2013-07-23 | 2013-07-23 | 一种酰胺类化合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103333168B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200117A1 (ar) * | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
CN108059638B (zh) * | 2017-02-16 | 2019-12-31 | 昆明医科大学 | 一类标记淀粉样蛋白的荧光探针及其制备方法与应用 |
CN108794485B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类toll样受体调节剂、其药物组合物、制备方法与用途 |
JP2021529161A (ja) | 2018-06-18 | 2021-10-28 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレーターとしてのピリジニルピラゾール |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
CN113416197B (zh) * | 2021-08-25 | 2021-12-28 | 北京鑫开元医药科技有限公司 | 甲酰胺类衍生物、制备方法、药物组合物及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012325971B2 (en) * | 2011-10-21 | 2016-03-31 | Glaxosmithkline Llc | Compounds and methods for enhancing innate immune responses |
-
2013
- 2013-07-23 CN CN201310311172.6A patent/CN103333168B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103333168A (zh) | 2013-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103333168B (zh) | 一种酰胺类化合物及其制备方法与应用 | |
RU2538507C2 (ru) | Фенилэтинильные производные в качестве ингибиторов вируса гепатита с | |
CA2835229A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
CN101628912B (zh) | 一类抗肿瘤含三氮唑杂环结构的化合物及其应用 | |
CN100494167C (zh) | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 | |
SG177289A1 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
JP6704422B2 (ja) | キナゾリン誘導体の塩およびその製造方法 | |
CN115894443B (zh) | 一种化合物艾奎斯韦及其应用 | |
CN104558093A (zh) | C21甾体皂苷苷元衍生物、其制备方法及其在制备抗肿瘤药物中的应用 | |
CN108586356A (zh) | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 | |
CN103694227A (zh) | 埃罗替尼衍生物及其制备方法和应用 | |
CN114920759A (zh) | 杂环-三氮唑并噻二唑杂环串联化合物、合成方法、药物组合物及用途 | |
CN105693738A (zh) | 3’-苯基螺[吲哚啉-3,2’-吡咯烷]-2-酮类衍生物及其制备方法和应用 | |
CN105130884A (zh) | 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途 | |
CN103819665B (zh) | 四价扎那米韦及其制备方法与应用 | |
CN107987017A (zh) | 一种3,4–二氢–2(1h)-喹啉酮类化合物及其制备方法与应用 | |
CN101260107B (zh) | 含4-噻唑烷酮和嘧啶双杂环化合物及其合成方法和应用 | |
CN114133390A (zh) | 一种去氢骆驼蓬碱衍生物及其制备方法和应用 | |
CN109879808B (zh) | 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途 | |
CN103626705A (zh) | 1-(3-苯甲酰氨基苄基)-1h-吲唑-3-甲酰胺类化合物及其制备方法和抗病毒用途 | |
CN109748828B (zh) | 1,8-二羟基-9,10-蒽醌衍生物、其制备方法及应用 | |
CN105837632A (zh) | 神经氨酸酶抑制剂及制备方法及在制备抗流感病毒药物中的应用 | |
CN109745302B (zh) | 大黄素衍生物、其制备方法及应用 | |
CN109796409A (zh) | 一种合成四氢吲唑化合物的方法 | |
CN110368386A (zh) | 一种含氧桥环化合物在制备治疗恶性肿瘤的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Tang Yefeng Inventor after: Zhang Linqi Inventor after: Wang Huan Inventor after: Wang Yongguang Inventor after: Jie Qing Inventor after: Huang Shengdian Inventor before: Tang Yefeng Inventor before: Zhang Linqi Inventor before: Wang Yongguang Inventor before: Jie Qing Inventor before: Huang Shengdian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TANG YEFENG ZHANG LINQI WANG YONGGUANG QING JIE HUANG SHENGDIAN TO: TANG YEFENG ZHANG LINQI WANG HUAN WANG YONGGUANG QING JIE HUANG SHENGDIAN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150805 |